
Waters Corporation WAT
$ 331.34
-0.56%
Quarterly report 2026-Q1
added 05-12-2026
Waters Corporation General and Administrative Expenses 2011-2026 | WAT
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Waters Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 240 M | 173 M | 736 M | 658 M | 627 M | 554 M | - | - | - | - | - | - | - | - | - | 445 M | 421 M | 427 M | 404 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 736 M | 173 M | 469 M |
Quarterly General and Administrative Expenses Waters Corporation
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 387 M | 214 M | 201 M | 175 M | - | 169 M | 173 M | 175 M | - | 187 M | 187 M | 182 M | - | 164 M | - | 157 M | 173 M | 153 M | 158 M | 143 M | 153 M | 135 M | 117 M | 148 M | 141 M | 126 M | 133 M | 134 M | 143 M | 127 M | 137 M | 130 M | 148 M | 135 M | 130 M | 131 M | 130 M | 124 M | 130 M | 129 M | 129 M | 125 M | 123 M | 120 M | 132 M | 122 M | 132 M | 127 M | 131 M | 121 M | 123 M | 119 M | 122 M | 115 M | 123 M | 117 M | 126 M | 121 M | 125 M | 117 M | 111 M | 107 M | 107 M | 103 M | 110 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 387 M | 103 M | 142 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Burning Rock Biotech Limited
BNR
|
490 M | $ 17.26 | -7.0 % | $ 181 M | ||
|
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M | ||
|
Co-Diagnostics
CODX
|
9.06 M | $ 1.34 | -17.79 % | $ 1.78 M | ||
|
Fulgent Genetics
FLGT
|
88.1 M | $ 15.78 | -2.53 % | $ 477 M | ||
|
Agilent Technologies
A
|
1.62 B | $ 112.09 | -1.02 % | $ 34.1 B | ||
|
Castle Biosciences
CSTL
|
229 M | $ 19.05 | 0.9 % | $ 552 M | ||
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
7.96 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
39.2 M | - | -61.36 % | $ 2.46 M | ||
|
Illumina
ILMN
|
1.09 B | $ 139.97 | -2.28 % | $ 22.3 B | ||
|
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M | ||
|
Interpace Biosciences
IDXG
|
9.48 M | $ 1.8 | -5.26 % | $ 7.96 M | ||
|
CareDx, Inc
CDNA
|
108 M | $ 19.83 | -3.22 % | $ 1.06 B | ||
|
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | ||
|
Lantheus Holdings
LNTH
|
275 M | $ 94.74 | -2.0 % | $ 6.39 B | ||
|
Check-Cap Ltd.
CHEK
|
2.37 M | - | - | $ 9.42 M | ||
|
HTG Molecular Diagnostics
HTGM
|
15.8 M | - | -20.0 % | $ 1.06 M | ||
|
Medpace Holdings
MEDP
|
198 M | $ 419.82 | 0.16 % | $ 12.1 B | ||
|
Mettler-Toledo International
MTD
|
998 M | $ 1 043.89 | 0.19 % | $ 21.5 B | ||
|
Myriad Genetics
MYGN
|
257 M | $ 3.6 | -0.69 % | $ 333 M | ||
|
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M | ||
|
NeoGenomics
NEO
|
273 M | $ 8.28 | -0.96 % | $ 1.06 B | ||
|
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
3.83 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
43.8 M | - | -11.32 % | $ 2.94 M | ||
|
National Research Corporation
NRC
|
54.8 M | $ 18.46 | -2.48 % | $ 413 M | ||
|
Charles River Laboratories International
CRL
|
743 M | $ 157.18 | -1.33 % | $ 7.79 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | ||
|
Natera
NTRA
|
589 M | $ 186.22 | -5.43 % | $ 18.3 B | ||
|
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K | ||
|
Koninklijke Philips N.V.
PHG
|
628 M | $ 25.27 | -0.94 % | $ 24 B | ||
|
Exact Sciences Corporation
EXAS
|
889 M | - | - | $ 19.8 B | ||
|
Guardant Health
GH
|
211 M | $ 92.95 | -5.79 % | $ 11.7 B | ||
|
Senseonics Holdings
SENS
|
52.5 M | $ 5.73 | -1.55 % | $ 239 M | ||
|
Personalis
PSNL
|
53.6 M | $ 6.47 | -3.64 % | $ 577 M | ||
|
Heska Corporation
HSKA
|
64.1 M | - | - | $ 1.31 B | ||
|
ICON Public Limited Company
ICLR
|
585 M | $ 117.95 | 0.73 % | $ 9.73 B | ||
|
Soleno Therapeutics
SLNO
|
132 M | $ 52.99 | -0.01 % | $ 2.69 B | ||
|
QIAGEN N.V.
QGEN
|
128 M | - | - | $ 10.6 B | ||
|
Twist Bioscience Corporation
TWST
|
247 M | $ 49.3 | -6.89 % | $ 2.95 B | ||
|
Biomerica
BMRA
|
2.98 M | $ 2.31 | -4.04 % | $ 5.31 M | ||
|
Laboratory Corporation of America Holdings
LH
|
2.22 B | $ 251.18 | -1.12 % | $ 20.9 B | ||
|
Thermo Fisher Scientific
TMO
|
8.73 B | $ 439.31 | -1.97 % | $ 166 B | ||
|
Trinity Biotech plc
TRIB
|
28.8 M | $ 0.57 | -1.49 % | $ 205 M | ||
|
Celcuity
CELC
|
27.2 M | $ 134.9 | 0.13 % | $ 6.31 B | ||
|
Motus GI Holdings
MOTS
|
6.58 M | - | -34.28 % | $ 263 K | ||
|
Neogen Corporation
NEOG
|
218 M | $ 8.27 | -1.9 % | $ 1.79 B |